Pharmacogenomics of Anti-platelet Intervention-2 (PAPI-2) Study: A Prospective, Multicenter, Randomized Trial of Genotype-directed (G-D)Versus Standard of Care (SOC)Anti-platelet Therapy.

Trial Profile

Pharmacogenomics of Anti-platelet Intervention-2 (PAPI-2) Study: A Prospective, Multicenter, Randomized Trial of Genotype-directed (G-D)Versus Standard of Care (SOC)Anti-platelet Therapy.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 30 Jun 2016

At a glance

  • Drugs Clopidogrel (Primary) ; Aspirin; Prasugrel
  • Indications Coronary artery disease; Coronary artery restenosis; Coronary disorders; Coronary stent thrombosis; Myocardial infarction; Stroke
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms PAPI-2
  • Most Recent Events

    • 25 Jan 2013 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 01 Oct 2012 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
    • 29 Feb 2012 Official Title amended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top